Wave Life Sciences (WVE) CSO details options, RSUs and share stake
Rhea-AI Filing Summary
Wave Life Sciences Ltd. Chief Scientific Officer Erik Ingelsson filed an initial ownership report showing his current equity position in the company. He directly holds 87,864 ordinary shares, including 17,489 shares and time-based RSUs that vest in annual installments from February 8, 2027 through February 8, 2030, subject to his continued service.
Ingelsson also holds three option awards to purchase ordinary shares: 350,000 shares at an exercise price of $5.85 expiring on May 8, 2034; 200,000 shares at $11.74 expiring on February 4, 2035; and 273,750 shares at $12.75 expiring on February 5, 2036. Each option vests over several years, with 25% vesting on an initial date and the remainder vesting quarterly, conditioned on continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Ingelsson Erik
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Share Option (Right to Buy) — 823,750 shares (Direct);
Ordinary Shares — 87,864 shares (Direct)
Footnotes (4)
- F1. Consists of (i) 17,489 ordinary shares, (ii) 24,750 RSUs that vest in three equal annual installments on February 8, 2027 through February 8, 2029; and (iii) 45,625 RSUs that vest in four equal annual installments of 25% beginning on February 8, 2027 through February 8, 2030, subject to the Reporting Person's continued service through the applicable vesting date.
- F2. The option vested as to 25% of the shares on May 8, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until May 8, 2028, subject to the Reporting Person's continued service through the applicable vesting date.
- F3. The option vested as to 25% of the shares on February 8, 2026, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2029, subject to the Reporting Person's continued service through the applicable vesting date.
- F4. The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030, subject to the Reporting Person's continued service through the applicable vesting date.
Key Figures
Direct ordinary shares: 87,864 shares
Current ordinary shares: 17,489 shares
RSUs vesting 2027–2029: 24,750 RSUs
+4 more
7 metrics
Direct ordinary shares
87,864 shares
Total ordinary shares directly held following Form 3
Current ordinary shares
17,489 shares
Component of direct holdings noted in footnote
RSUs vesting 2027–2029
24,750 RSUs
Vest in three equal annual installments from Feb 8, 2027–2029
RSUs vesting 2027–2030
45,625 RSUs
Vest in four equal annual installments from Feb 8, 2027–2030
Option at $5.85
350,000 shares
Share option, exercise price $5.85, expires May 8, 2034
Option at $11.74
200,000 shares
Share option, exercise price $11.74, expires Feb 4, 2035
Option at $12.75
273,750 shares
Share option, exercise price $12.75, expires Feb 5, 2036
Key Terms
Share Option (Right to Buy), RSUs, Ordinary Shares, vesting, +1 more
5 terms
RSUs financial
"24,750 RSUs that vest in three equal annual installments"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
vesting financial
"RSUs that vest in three equal annual installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Chief Scientific Officer financial
"officer_title: "Chief Scientific Officer""
FAQ
What does Wave Life Sciences (WVE) Form 3 report for Erik Ingelsson?
The Form 3 shows Chief Scientific Officer Erik Ingelsson’s initial ownership in Wave Life Sciences, including 87,864 ordinary shares, multiple RSU awards vesting through 2030, and several stock option grants with exercise prices between $5.85 and $12.75 per share.
What stock options does the WVE Chief Scientific Officer hold?
He holds three option grants to buy Wave Life Sciences ordinary shares: 350,000 shares at $5.85 expiring May 8, 2034; 200,000 shares at $11.74 expiring February 4, 2035; and 273,750 shares at $12.75 expiring February 5, 2036, all vesting over multiple years.
How do Erik Ingelsson’s RSUs at Wave Life Sciences vest?
He has 24,750 RSUs vesting in three equal annual installments on February 8, 2027–2029, and 45,625 RSUs vesting in four equal annual installments starting February 8, 2027 through February 8, 2030. Vesting depends on his continued service with the company.
AI-generated analysis. How Rhea-AI works. Not financial advice.
